Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P21802
UPID:
FGFR2_HUMAN
Alternative names:
K-sam; Keratinocyte growth factor receptor
Alternative UPACC:
P21802; B4DFC2; E7EVR6; E9PCR0; P18443; Q01742; Q12922; Q14300; Q14301; Q14302; Q14303; Q14304; Q14305; Q14672; Q14718; Q14719; Q1KHY5; Q86YI4; Q8IXC7; Q96KL9; Q96KM0; Q96KM1; Q96KM2; Q9NZU2; Q9NZU3; Q9UD01; Q9UD02; Q9UIH3; Q9UIH4; Q9UIH5; Q9UIH6; Q9UIH7; Q9UIH8; Q9UM87; Q9UMC6; Q9UNS7; Q9UQH7; Q9UQH8; Q9UQH9; Q9UQI0
Background:
Fibroblast growth factor receptor 2 (FGFR2), also known as Keratinocyte growth factor receptor and K-sam, is pivotal in cell proliferation, differentiation, migration, apoptosis, and embryonic development. It orchestrates osteogenesis, lung morphogenesis, and skin development by engaging in signaling cascades upon ligand binding, influencing cellular outcomes through pathways like MAPK and AKT1.
Therapeutic significance:
FGFR2's mutations are linked to various craniosynostosis syndromes, including Crouzon, Jackson-Weiss, and Apert syndromes, highlighting its critical role in skeletal development. Understanding FGFR2's function could unveil novel therapeutic avenues for these genetic disorders, offering hope for targeted treatments.